Lung cancer trials in South Korea
168 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Cheongju-si, Daegu, Goyang-si, Seongnam, Seoul, Suwon
- Age
- 18 years and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00 - Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Bupyeong-gu, Daegu, Hwasun, Incheon, Junggu, Seoul, Suwon, Yangsan
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 3Taking peopleA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Where
- Cheongju-si, Daegu, Seongnam, Seoul, Suwon
- Age
- 18 years and over
- People
- 530 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00 - Phase 3Taking peopleA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Where
- Changwon, Cheongju Chungcheongbuk-do, Daegu, Gyeonggi-do, Seongnam-si Gyeonggi-do, Seoul, Suwon Gyeonggi-do, Ulsan
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07099898 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Busan, Daejeon, Jeollanam-do, Seoul, Yangsan
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 2Taking peopleKEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
- Where
- Seoul
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07252739 · EU 2025-521939-36-00 - Phase 3Taking peoplePhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Where
- Goyang-si, Incheon, Seoul, Suwon
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00 - Phase 1Taking peopleA Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
- Where
- Seoul
- Age
- 18 years and over
- People
- 102
- Run by
- IntoCell, Inc
See details and how to joinNCT07423117 - Phase 3Taking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Daegu, Goyang-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - Phase 3Taking peopleDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Busan, Daejoen, Goyang, Hwasun, Seongnam, Seoul
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00 - Phase 3Taking peopleA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Where
- Cheongju-si, Daegu, Goyang-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00 - Phase 3Taking peopleStudy of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Where
- Buk-Gu, Cheongju-si, Dalseo, Goyang-si, Gyeongsangnam-do, Hwasun-Gun, Seocho -Gu, Seongnam-si, Seoul, Songpa-Gu
- Age
- 18 years and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00 - Phase 3Taking peopleA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Where
- Busan, Cheongju-si, Daegu, Deagu, Goyang-si, Hwasun, Namdong-gu, Seongnam-si, Seoul, Yangsan
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01 - Phase 3Taking peopleA Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Goyang-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00 - Phase 1/2Taking peopleA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- Where
- Seoul
- Age
- 18 years to 64 years
- People
- 170 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00 - Phase 2Taking peopleBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
- Where
- Seoul
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07486817 · EU 2025-523567-38-00 - Phase 3Taking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Cheongju-si, Goyang-si, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Busan, Daegu, Daejeon, Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01 - Phase 1/2Taking peopleStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Where
- Busan, Cheongju-si, Gyeonggi-do, Hwasun, Incheon, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- Inhibrx Biosciences, Inc
See details and how to joinNCT04198766 - Phase 1/2Taking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Goyang-si, Seoul
- Age
- 12 years and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Busan, Goyang-si Gyeonggi-do, Incheon, Seoul, Yangsan-si, Gyeongsangnam-do
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 3Taking peopleStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Where
- Cheongju-si, Gyeonggi-do, Hwasun, Seoul
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Revolution Medicines, Inc.
See details and how to joinNCT06881784 · EU 2024-518154-16-00 - Phase 1Taking peopleA Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Where
- Haeundae, Seoul
- Age
- 18 years to 99 years
- People
- 600 worldwide
- Run by
- Erasca, Inc.
See details and how to joinNCT06983743 · EU 2026-525794-39-00 - Phase 1/2Taking peopleA Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
- Where
- Cheongju-si, Seongnam-si, Seoul, Suwon
- Age
- 18 years and over
- People
- 315 worldwide
- Run by
- Voronoi, Inc
See details and how to joinNCT07699328 · EU 2025-523122-40-00 - No phaseTaking peoplePatient-Specific MRD Liquid Biopsy in Resected NSCLC: Plasma and Bronchial Washing ctDNA
- Where
- Seoul, Yongin-si
- Age
- 19 years and over
- People
- 40
- Run by
- Eun Hye Lee
See details and how to joinNCT07921888